High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1151-1156

  Bouvard, B ^a   Hoppe E ^a   Soulie P ^b   Georgin Mege, M ^b   Jadaud, E ^b   Abadie Lacourtoisie, S ^b   Petit le manac'h, A ^a   Laffitte, A ^a   Levasseur, R ^a   Audran, M ^a   Chappard, D ^a   Legrand, E ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b Paul Papin Cancer Institute   (France)

Author keywords

25 hydroxyvitamin D; Aromatase inhibitor; Breast cancer; Osteoporosis; Vertebral fracture

Indexed keywords

25 HYDROXYVITAMIN D; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BREAST CANCER; CANCER LOCALIZATION; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPINE RADIOGRAPHY; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; PREVALENCE; SPINAL FRACTURES; SPINE;

EID: 84860467613     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr356     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
4. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
5. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
6. Hiscox S, Davies EL, Barrett-Lee P. Aromatase inhibitors in breast cancer. Maturitas 2009; 63: 275-279.
7. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26: 1051-1057.
8. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3629-3635.
9. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8: 119-127.
10. Rabaglio M, Sun Z, Price KN et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20: 1489-1498.
11. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-1148.
12. Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2006; 366: 81-89.
13. Lee JH, O'Keefe JH, Bell D et al. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52: 1949-1956.
14. Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145-158.
15. McCarthy K, Laban C, Bustin SA et al. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. Anticancer Res 2009; 29: 155-157.
16. Lappe JM, Travers-Gustafson D, Davies KM et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586-1591.
17. Chlebowski RT, Johnson KC, Kooperberg C et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008; 100: 1581-1591.
18. Goodwin PJ, Ennis M, Pritchard KI et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-3763.
19. Confavreux CB, Fontana A, Guastalla JP et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007; 41: 346-352.
20. Geisler J, Lonning PE, Krag LE et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006; 42: 2968-2975.
21. Rejnmark L, Vestergaard P, Brot C, Mosekilde L. Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 2011; 88: 238-245.
22. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416.
23. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (Suppl 1): S3-S18.
24. Hadji P, Aapro MS, Body JJ et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011; 22: 2546-2555.
25. Chen Z, Maricic M, Pettinger M et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 2005; 104: 1520-1530.
26. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005; 16 (Suppl 2): S3-S7.
27. Warriner AH, Patkar NM, Curtis JR et al. Which fractures are most attributable to osteoporosis? J Clin Epidemiol 2011; 64: 46-53.
28. O'Neill TW, Felsenberg D, Varlow J et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11: 1010-1018.
29. Oleksik A, Lips P, Dawson A et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000; 15: 1384-1392.
30. Cooper C, Atkinson EJ, Jacobsen SJ et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993; 137: 1001-1005.
31. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513-521.
32. Chen Z, Maricic M, Bassford TL et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005; 165: 552-558.
33. Mincey BA, Duh MS, Thomas SK et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006; 7: 127-132.
34. Van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48: 3224-3229.
35. Griffith JF, Engelke K, Genant HK. Looking beyond bone mineral density: imaging assessment of bone quality. Ann N Y Acad Sci 2010; 1192: 45-56.